This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

'Fast Money' Recap: Confused Investors

NEW YORK ( TheStreet) --  The S&P 500 closed ever so slightly higher after a much lower-than-expected nonfarm payrolls report for December. 

Brian Kelly, founder of Brian Kelly Capital, said investors are definitely confused. He added that the Federal Reserve will still go through with its tapering plans and he remains short the S&P 500. 

Tim Seymour, managing partner of Triogem Asset Management, said gold is likely to sell off around Jan. 28 or Jan. 29 when the Fed confirms it will go through with its tapering plans. He would look to take profits in the iShares MSCI Emerging Markets ETF (EEM) at $40.25. 

Steve Grasso, director of institutional sales at Stuart Frankel, said the earnings from financial stocks next week are unlikely to cause a selloff in the market. However, he said a selloff could happen in February or March. 

Intercept Pharmaceuticals (ICPT) is up 517% over the past two days. Dr. Yaron Weber, who leads Citigroup's biotech research team, said ICPT's obeticholic acid was so successful in its treatment of the chronic liver disease nonalcoholic steatohepapatitis that its trials were stopped early. 

He added that even his own sales estimates are considered conservative if the drug comes to market. Currently, he predicts sales of roughly $4 billion, making ICPT a potential merger candidate. 

As for other biotech names, he likes Celgene (CELG), which will give guidance on Monday at the JPMorgan Healthcare Conference. Analysts expect $7.30 in earnings per share for the year, while Weber is looking for $7.60. He said Clovis Oncology (CLVS) is his top "under the radar" pick. Guy Adami, managing director of, said his pick continues to be CELG. 

Target (TGT) announced its credit card data breach could now affect 110 million people because of the compromised names, addresses, phone numbers or email addresses. Adami said he's still a buyer of the stock with a stop-loss at $62.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,065.18 -6.04 -0.04%
S&P 500 1,970.44 -7.36 -0.37%
NASDAQ 4,483.9160 -21.9360 -0.49%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs